Journey Medical
DERM
68 hedge funds and large institutions have $61.9M invested in Journey Medical in 2025 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 5 closing their positions.
1,200% more capital inflows, than outflows
Capital inflows: $17.3M | Capital outflows: $1.33M
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
24% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 17
21% more funds holding
Funds holding: 56 → 68 (+12)
5.25% more ownership
Funds ownership: 37.55% → 42.8% (+5.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$6.35M |
| 2 |
Summit Financial
Parsippany,
New Jersey
|
+$2.76M |
| 3 |
Pale Fire Capital SE
Prague,
Czech Republic
|
+$1.42M |
| 4 |
Wasatch Advisors
Salt Lake City,
Utah
|
+$1.12M |
| 5 |
Sheets Smith Investment Management
Houston,
Texas
|
+$964K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$226K |
| 2 |
PVG Asset Management
Golden,
Colorado
|
-$122K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$110K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$98.1K |
| 5 |
Quadrature Capital
London,
United Kingdom
|
-$94.4K |
DERM Hedge Fund Activity: Q3 2025 in Review
68 of the 7,650 institutional investors tracked by Wall St. Rank reported a position in Journey Medical (DERM) for Q3 2025, worth a combined $61.9M — up 33% from $46.6M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new DERM positions and 5 closed out — a net gain of 12 holders — while 21 added to existing stakes and 17 trimmed.
The largest buyer was Opaleye Management, adding an estimated $6.35M. The largest seller was Morgan Stanley, cutting an estimated $226K.
- 68 institutional investors held Journey Medical (DERM) as of Q3 2025, up from 56 in Q2 2025.
- Funds reported $61.9M of Journey Medical stock for Q3 2025, up 33% quarter-over-quarter.
- 17 funds opened new Journey Medical positions in Q3 2025 and 5 closed out, a net change of +12 holders.
- The largest Journey Medical buyer in Q3 2025 was Opaleye Management, an estimated $6.35M added.
- The largest Journey Medical seller in Q3 2025 was Morgan Stanley, an estimated $226K sold.
Based on aggregated 13F filings for Q3 2025.